Thomas H. Silberg
Chief Executive Officer
Thomas H. Silberg is currently CEO of StemProtein, LLC. He has more than 30 years of experience as a seasoned professional in the Pharmaceutical and Biopharmaceutical Industries, including Genway Biotech, Hoffmann-La Roche, Ligand Pharmaceuticals, Abraxis Bioscience, and APP Pharmaceuticals. He has led multiple strategic transactions, including company divestitures, asset acquisitions, and partnerships, and has consistently grown both revenue and earnings. Serving as President and CEO of APP Pharmaceuticals, he led the company to become the second largest U.S. provider of generic injectables in only four years.
Tom is a graduate of the University of Minnesota, where he earned a BS degree in Advertising and Marketing. His past Board appointments include the USC Center of Excellence in HealthCare Management, Medi Promotions, the Cobalis Corporation, and the Generic Pharmaceutical Manufacturers Association.
He is currently a member of the Board of Directors for Pivotal Biosciences, CardioCell, LLC, and StemCutis, LLC, and serves as Chairman of the Board for Genway Biotech, Inc., and the Palomar Health System Foundation.